Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 187

1.

Inhibition of human CYP1 enzymes by a classical inhibitor α-naphthoflavone and a novel inhibitor N-(3, 5-dichlorophenyl)cyclopropanecarboxamide: An in vitro and in silico study.

Juvonen RO, Jokinen EM, Javaid A, Lehtonen M, Raunio H, Pentikäinen OT.

Chem Biol Drug Des. 2020 Feb 14. doi: 10.1111/cbdd.13669. [Epub ahead of print]

PMID:
32060993
2.

In vitro sulfonation of 7-hydroxycoumarin derivatives in liver cytosol of human and six animal species.

Juvonen RO, Pentikäinen O, Huuskonen J, Timonen J, Kärkkäinen O, Heikkinen A, Fashe M, Raunio H.

Xenobiotica. 2020 Jan 8:1-9. doi: 10.1080/00498254.2020.1711544. [Epub ahead of print]

PMID:
31903849
3.

In vitro glucuronidation of 7-hydroxycoumarin derivatives in intestine and liver microsomes of Beagle dogs.

Juvonen RO, Heikkinen AT, Kärkkäinen O, Jehangir R, Huuskonen J, Troberg J, Raunio H, Pentikäinen OT, Finel M.

Eur J Pharm Sci. 2020 Jan 1;141:105118. doi: 10.1016/j.ejps.2019.105118. Epub 2019 Oct 25.

PMID:
31669387
4.

Metabolism of Scoparone in Experimental Animals and Humans.

Juvonen RO, Novák F, Emmanouilidou E, Auriola S, Timonen J, Heikkinen AT, Küblbeck J, Finel M, Raunio H.

Planta Med. 2019 Apr;85(6):453-464. doi: 10.1055/a-0835-2301. Epub 2019 Feb 8.

PMID:
30736072
5.

Development of new Coumarin-based profluorescent substrates for human cytochrome P450 enzymes.

Juvonen RO, Ahinko M, Huuskonen J, Raunio H, Pentikäinen OT.

Xenobiotica. 2019 Sep;49(9):1015-1024. doi: 10.1080/00498254.2018.1530399. Epub 2018 Nov 29.

PMID:
30272491
6.

Blocking oestradiol synthesis pathways with potent and selective coumarin derivatives.

Niinivehmas S, Postila PA, Rauhamäki S, Manivannan E, Kortet S, Ahinko M, Huuskonen P, Nyberg N, Koskimies P, Lätti S, Multamäki E, Juvonen RO, Raunio H, Pasanen M, Huuskonen J, Pentikäinen OT.

J Enzyme Inhib Med Chem. 2018 Dec;33(1):743-754. doi: 10.1080/14756366.2018.1452919.

7.

Structure-Activity Relationship Analysis of 3-Phenylcoumarin-Based Monoamine Oxidase B Inhibitors.

Rauhamäki S, Postila PA, Niinivehmas S, Kortet S, Schildt E, Pasanen M, Manivannan E, Ahinko M, Koskimies P, Nyberg N, Huuskonen P, Multamäki E, Pasanen M, Juvonen RO, Raunio H, Huuskonen J, Pentikäinen OT.

Front Chem. 2018 Mar 2;6:41. doi: 10.3389/fchem.2018.00041. eCollection 2018.

8.

Molecular Docking-Based Design and Development of a Highly Selective Probe Substrate for UDP-glucuronosyltransferase 1A10.

Juvonen RO, Rauhamäki S, Kortet S, Niinivehmas S, Troberg J, Petsalo A, Huuskonen J, Raunio H, Finel M, Pentikäinen OT.

Mol Pharm. 2018 Mar 5;15(3):923-933. doi: 10.1021/acs.molpharmaceut.7b00871. Epub 2018 Feb 15.

9.

Comparison of In Vitro Hepatic Scoparone 7-O-Demethylation between Humans and Experimental Animals.

Fayyaz A, Makwinja S, Auriola S, Raunio H, Juvonen RO.

Planta Med. 2018 Mar;84(5):320-328. doi: 10.1055/s-0043-119886. Epub 2017 Sep 26.

PMID:
28950382
10.

A liquid chromatography-tandem mass spectrometry analysis of nine cytochrome P450 probe drugs and their corresponding metabolites in human serum and urine.

Puris E, Pasanen M, Gynther M, Häkkinen MR, Pihlajamäki J, Keränen T, Honkakoski P, Raunio H, Petsalo A.

Anal Bioanal Chem. 2017 Jan;409(1):251-268. doi: 10.1007/s00216-016-9994-x. Epub 2016 Oct 12.

PMID:
27734142
11.

[Drug therapy and the most common drugs for childhood psychiatric disorders].

Puustjärvi A, Raunio H, Lecklin A, Kumpulainen K.

Duodecim. 2016;132(10):943-50. Review. Finnish.

PMID:
27382830
12.

Common and Distinct Interactions of Chemical Inhibitors with Cytochrome P450 CYP1A2, CYP2A6 and CYP2B6 Enzymes.

Raunio H, Juvonen RO, Poso A, Lahtela-Kakkonen M, Rahnasto-Rilla M.

Drug Metab Lett. 2016;10(1):56-64.

PMID:
26648056
13.

Ultrafast protein structure-based virtual screening with Panther.

Niinivehmas SP, Salokas K, Lätti S, Raunio H, Pentikäinen OT.

J Comput Aided Mol Des. 2015 Oct;29(10):989-1006. doi: 10.1007/s10822-015-9870-3. Epub 2015 Sep 25.

PMID:
26407559
14.

Time-Dependent Inhibition of CYP2C19 by Isoquinoline Alkaloids: In Vitro and In Silico Analysis.

Salminen KA, Rahnasto-Rilla M, Väänänen R, Imming P, Meyer A, Horling A, Poso A, Laitinen T, Raunio H, Lahtela-Kakkonen M.

Drug Metab Dispos. 2015 Dec;43(12):1891-904. doi: 10.1124/dmd.115.065755. Epub 2015 Sep 23.

PMID:
26400396
15.

Modeling of interactions between xenobiotics and cytochrome P450 (CYP) enzymes.

Raunio H, Kuusisto M, Juvonen RO, Pentikäinen OT.

Front Pharmacol. 2015 Jun 12;6:123. doi: 10.3389/fphar.2015.00123. eCollection 2015. Review.

16.

Inhibitory effects and oxidation of 6-methylcoumarin, 7-methylcoumarin and 7-formylcoumarin via human CYP2A6 and its mouse and pig orthologous enzymes.

Juvonen RO, Kuusisto M, Fohrgrup C, Pitkänen MH, Nevalainen TJ, Auriola S, Raunio H, Pasanen M, Pentikäinen OT.

Xenobiotica. 2016;46(1):14-24. doi: 10.3109/00498254.2015.1048327. Epub 2015 Jun 11.

PMID:
26068522
17.

Rational design of novel CYP2A6 inhibitors.

Tani N, Juvonen RO, Raunio H, Fashe M, Leppänen J, Zhao B, Tyndale RF, Rahnasto-Rilla M.

Bioorg Med Chem. 2014 Dec 1;22(23):6655-6664. doi: 10.1016/j.bmc.2014.10.001. Epub 2014 Oct 13.

PMID:
25458499
18.

From pharmacogenomics to integrated personal omics profiling: a gap in implementation into healthcare.

Carlberg C, Raunio H.

Per Med. 2014 Sep;11(7):625-629. doi: 10.2217/pme.14.38. No abstract available.

PMID:
29764051
19.

Preclinical pharmacology of FL442, a novel nonsteroidal androgen receptor modulator.

Poutiainen PK, Huhtala T, Jääskeläinen T, Petsalo A, Küblbeck J, Kaikkonen S, Palvimo JJ, Raunio H, Närvänen A, Peräkylä M, Juvonen RO, Honkakoski P, Laatikainen R, Pulkkinen JT.

Mol Cell Endocrinol. 2014 Apr 25;387(1-2):8-18. doi: 10.1016/j.mce.2014.02.008. Epub 2014 Feb 22.

PMID:
24565895
20.

Interactions of inhibitor molecules with the human CYP2E1 enzyme active site.

Martikainen LE, Rahnasto-Rilla M, Neshybova S, Lahtela-Kakkonen M, Raunio H, Juvonen RO.

Eur J Pharm Sci. 2012 Dec 18;47(5):996-1005. doi: 10.1016/j.ejps.2012.09.018. Epub 2012 Oct 13.

PMID:
23069620
21.

Design, synthesis, and evaluation of novel cyclic phosphates of 5-aminosalicylic acid as cytochrome p450-activated prodrugs.

Huttunen KM, Tani N, Juvonen RO, Raunio H, Rautio J.

Mol Pharm. 2013 Feb 4;10(2):532-7. doi: 10.1021/mp300330v. Epub 2012 Aug 31.

PMID:
22937971
22.

Preservation, induction or incorporation of metabolism into the in vitro cellular system - views to current opportunities and limitations.

Pelkonen O, Turpeinen M, Hakkola J, Abass K, Pasanen M, Raunio H, Vähäkangas K.

Toxicol In Vitro. 2013 Aug;27(5):1578-83. doi: 10.1016/j.tiv.2012.06.002. Epub 2012 Jun 19.

PMID:
22728233
23.

CYP2A6: genetics, structure, regulation, and function.

Raunio H, Rahnasto-Rilla M.

Drug Metabol Drug Interact. 2012 May 5;27(2):73-88. doi: 10.1515/dmdi-2012-0001. Review.

PMID:
22706231
24.

Function and regulation of the Cyp2a5/CYP2A6 genes in response to toxic insults in the liver.

Abu-Bakar A, Hakkola J, Juvonen R, Rahnasto-Rilla M, Raunio H, Lang MA.

Curr Drug Metab. 2013 Jan;14(1):137-50. Review.

PMID:
22497566
25.

Metabolism of bilirubin by human cytochrome P450 2A6.

Abu-Bakar A, Arthur DM, Wikman AS, Rahnasto M, Juvonen RO, Vepsäläinen J, Raunio H, Ng JC, Lang MA.

Toxicol Appl Pharmacol. 2012 May 15;261(1):50-8. doi: 10.1016/j.taap.2012.03.010. Epub 2012 Mar 24.

PMID:
22465937
26.

Antifungal activities of novel non-azole molecules against S. cerevisiae and C. albicans.

Tani N, Rahnasto-Rilla M, Wittekindt C, Salminen KA, Ritvanen A, Ollakka R, Koskiranta J, Raunio H, Juvonen RO.

Eur J Med Chem. 2012 Jan;47(1):270-7. doi: 10.1016/j.ejmech.2011.10.053. Epub 2011 Nov 6.

PMID:
22100140
27.

Identification of novel CYP2A6 inhibitors by virtual screening.

Rahnasto MK, Raunio HA, Wittekindt C, Salminen KA, Leppänen J, Juvonen RO, Poso A, Lahtela-Kakkonen MK.

Bioorg Med Chem. 2011 Dec 1;19(23):7186-93. doi: 10.1016/j.bmc.2011.09.054. Epub 2011 Oct 4.

PMID:
22019468
28.

CYP2C19 progress curve analysis and mechanism-based inactivation by three methylenedioxyphenyl compounds.

Salminen KA, Meyer A, Imming P, Raunio H.

Drug Metab Dispos. 2011 Dec;39(12):2283-9. doi: 10.1124/dmd.111.041319. Epub 2011 Sep 9.

PMID:
21908684
29.

In silico toxicology - non-testing methods.

Raunio H.

Front Pharmacol. 2011 Jun 30;2:33. doi: 10.3389/fphar.2011.00033. eCollection 2011.

30.

In vivo-in vitro-in silico pharmacokinetic modelling in drug development: current status and future directions.

Pelkonen O, Turpeinen M, Raunio H.

Clin Pharmacokinet. 2011 Aug;50(8):483-91. doi: 10.2165/11592400-000000000-00000.

PMID:
21740072
31.

Prodrugs--from serendipity to rational design.

Huttunen KM, Raunio H, Rautio J.

Pharmacol Rev. 2011 Sep;63(3):750-71. doi: 10.1124/pr.110.003459. Epub 2011 Jul 7. Review.

PMID:
21737530
32.

Simple, direct, and informative method for the assessment of CYP2C19 enzyme inactivation kinetics.

Salminen KA, Leppänen J, Venäläinen JI, Pasanen M, Auriola S, Juvonen RO, Raunio H.

Drug Metab Dispos. 2011 Mar;39(3):412-8. doi: 10.1124/dmd.110.036376. Epub 2010 Dec 9.

PMID:
21148250
33.

Cytochrome P450-mediated pulmonary metabolism of carcinogens: regulation and cross-talk in lung carcinogenesis.

Anttila S, Raunio H, Hakkola J.

Am J Respir Cell Mol Biol. 2011 May;44(5):583-90. doi: 10.1165/rcmb.2010-0189RT. Epub 2010 Nov 19. Review.

PMID:
21097654
34.

Inhibition of human drug metabolizing cytochrome P450 enzymes by plant isoquinoline alkaloids.

Salminen KA, Meyer A, Jerabkova L, Korhonen LE, Rahnasto M, Juvonen RO, Imming P, Raunio H.

Phytomedicine. 2011 Apr 15;18(6):533-8. doi: 10.1016/j.phymed.2010.08.012. Epub 2010 Sep 20.

PMID:
20851588
35.

From known knowns to known unknowns: predicting in vivo drug metabolites.

Pelkonen O, Tolonen A, Korjamo T, Turpeinen M, Raunio H.

Bioanalysis. 2009 May;1(2):393-414. doi: 10.4155/bio.09.32. Review.

PMID:
21083174
36.

Cytochrome P450-activated prodrugs: targeted drug delivery.

Huttunen KM, Mähönen N, Raunio H, Rautio J.

Curr Med Chem. 2008;15(23):2346-65. Review.

PMID:
18855665
37.

Inhibition and induction of human cytochrome P450 enzymes: current status.

Pelkonen O, Turpeinen M, Hakkola J, Honkakoski P, Hukkanen J, Raunio H.

Arch Toxicol. 2008 Oct;82(10):667-715. doi: 10.1007/s00204-008-0332-8. Epub 2008 Jul 11. Review.

PMID:
18618097
38.

Nicotine metabolism and urinary elimination in mouse: in vitro and in vivo.

Raunio H, Pokela N, Puhakainen K, Rahnasto M, Mauriala T, Auriola S, Juvonen RO.

Xenobiotica. 2008 Jan;38(1):34-47.

PMID:
18098062
39.

Lääkkeiden kliinisesti merkittävät yhteisvaikutukset sairaalassa.

Mensio S, Ojala R, Raunio H.

Duodecim. 2007;123(14):1725-31. Finnish. No abstract available.

PMID:
18027826
40.

Identification of inhibitors of the nicotine metabolising CYP2A6 enzyme--an in silico approach.

Rahnasto M, Wittekindt C, Juvonen RO, Turpeinen M, Petsalo A, Pelkonen O, Poso A, Stahl G, Höltje HD, Raunio H.

Pharmacogenomics J. 2008 Oct;8(5):328-38. Epub 2007 Oct 9.

PMID:
17923852
41.

Transcription factor binding to a putative double E-box motif represses CYP3A4 expression in human lung cells.

Biggs JS, Wan J, Cutler NS, Hakkola J, Uusimäki P, Raunio H, Yost GS.

Mol Pharmacol. 2007 Sep;72(3):514-25. Epub 2007 Jun 4.

PMID:
17548528
42.

Novel cyclic phosphate prodrug approach for cytochrome P450-activated drugs containing an alcohol functionality.

Huttunen KM, Mähönen N, Leppänen J, Vepsäläinen J, Juvonen RO, Raunio H, Kumpulainen H, Järvinen T, Rautio J.

Pharm Res. 2007 Apr;24(4):679-87. Epub 2007 Feb 15.

PMID:
17372695
43.

New potent and selective cytochrome P450 2B6 (CYP2B6) inhibitors based on three-dimensional quantitative structure-activity relationship (3D-QSAR) analysis.

Korhonen LE, Turpeinen M, Rahnasto M, Wittekindt C, Poso A, Pelkonen O, Raunio H, Juvonen RO.

Br J Pharmacol. 2007 Apr;150(7):932-42. Epub 2007 Feb 26.

44.

The functional role of CYP2B6 in human drug metabolism: substrates and inhibitors in vitro, in vivo and in silico.

Turpeinen M, Raunio H, Pelkonen O.

Curr Drug Metab. 2006 Oct;7(7):705-14. Review.

PMID:
17073575
45.

In vitro screening of drug metabolism during drug development: can we trust the predictions?

Pelkonen O, Raunio H.

Expert Opin Drug Metab Toxicol. 2005 Jun;1(1):49-59. Review.

PMID:
16922652
46.

Cytochrome P450 (CYP) inhibition screening: comparison of three tests.

Turpeinen M, Korhonen LE, Tolonen A, Uusitalo J, Juvonen R, Raunio H, Pelkonen O.

Eur J Pharm Sci. 2006 Oct 1;29(2):130-8. Epub 2006 Jun 27.

PMID:
16890411
47.

Use of an online surveillance system for screening drug interactions in prescriptions in community pharmacies.

Heikkilä T, Lekander T, Raunio H.

Eur J Clin Pharmacol. 2006 Aug;62(8):661-5. Epub 2006 Jun 22.

PMID:
16791585
48.

Evaluation of hydroxyimine as cytochrome P450-selective prodrug structure.

Kumpulainen H, Mähönen N, Laitinen ML, Jaurakkajärvi M, Raunio H, Juvonen RO, Vepsäläinen J, Järvinen T, Rautio J.

J Med Chem. 2006 Feb 9;49(3):1207-11.

PMID:
16451086
49.

Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors.

Korhonen LE, Rahnasto M, Mähönen NJ, Wittekindt C, Poso A, Juvonen RO, Raunio H.

J Med Chem. 2005 Jun 2;48(11):3808-15.

PMID:
15916432
50.

Prediction of drug metabolism and interactions on the basis of in vitro investigations.

Pelkonen O, Turpeinen M, Uusitalo J, Rautio A, Raunio H.

Basic Clin Pharmacol Toxicol. 2005 Mar;96(3):167-75. Review.

Supplemental Content

Loading ...
Support Center